Company news
Telomir Pharmaceuticals, Inc. news in 2026
Telomir Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.
Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer
November 18, 2026
Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
October 6, 2026
Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)
September 17, 2026
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
September 14, 2026
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
August 10, 2026
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
June 14, 2026
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
May 20, 2026
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
April 30, 2026
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1
April 27, 2026
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
April 23, 2026
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models
February 17, 2026
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
February 5, 2026
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
January 5, 2026
Decks in 2026
- Investor Presentation (July 2026)
Investor deck · 25 slides · July 2026
- Investor Presentation (April 2026)
Investor deck · 43 slides · April 2026
- Investor Presentation (February 2026)
Investor deck · 70 slides · February 2026